Barrett is Founder and CEO of Nabsys. He is passionate about the impact that advanced technology can have on the understanding of disease as well as on its diagnosis and treatment. He has raised $150 million to realize a new way of analyzing DNA that uses proprietary solid-state electronic nanodetectors to analyze very long molecules, with an initial focus on genomic structural variation.
Barrett is an adjunct professor at Brown University where he lectures on the rapidly evolving business of life sciences. He serves as a commissioner of the I-195 Redevelopment District Commission, a major land redevelopment initiative in downtown Providence, RI with a focus on life sciences and other high-technology sectors. He has received numerous awards including, in 2011, Rhode Island Innovator of the Year, and in 2018, a career achievement award from the Warren Alpert Medical School of Brown University. Barrett graduated from the highly competitive Program in Liberal Medical Education (PLME) at Brown University where he received an M.D. and an Sc.B. in Physics and won the undergraduate physics award (the Lindsay Prize) and the Galletti Prize for physics in medicine.
When he is not working, teaching, or volunteering, Barrett enjoys spending time with his wife and two young children. He also enjoys architecture and collecting antique/ancient sculpture. He has visited 60 countries, including Spain, where he has run with the Bulls in Pamplona.
John Oliver, PhD.
John Oliver has directed the research efforts at Nabsys since he joined the company in March 2007. Dr. Oliver brings over 25 years of research expertise to Nabsys. His diverse experience includes synthetic organic chemistry, biochemistry, molecular biology, surface chemistry, and microarray technology. He previously served as Chief Scientific Officer at GeneSpectrum Inc. an array based sequencing company that he co-founded in 2000 with two colleagues from Brown University until it was acquired by Nabsys. GeneSpectrum utilized novel probe designs incorporating non-natural nucleosides to increase the information content of oligonucleotide arrays by over 1000-fold. Prior to founding GeneSpectrum, Dr. Oliver was an assistant professor of Chemistry at Brown University. His research group focused on developing methods of performing non-natural amino acid mutagenesis, identifying novel catalysis mechanisms, and investigating biosynthetic pathways for terpene natural products. Dr. Oliver earned his MS and PhD from Northwestern University in Evanston, IL and received his BS in Chemistry from Harvey Mudd College in Claremont, CA. In his spare time, and depending on the season, Dr. Oliver enjoys research into the feeding habits of several species of trout using synthetic food sources of his own making, or investigating the optimal snowpack density for high speed flotation.
Justin is responsible for the commercialization of Nabsys’ OhmX platform and the democratization of structural variant analysis. He was previously part of CENTOGENE GmbH Executive Leadership Team as the Senior Vice President of Business Development where he managed the company’s commercial business. Prior to CENTOGENE, Justin was the Head of Business Development at Synthetic Genomics, Inc. a synthetic biology company responsible for the launch and commercialization of the first bench top DNA assembly system. Justin has held scientific roles at both the Genomics Institute of the Novartis Research Foundation (GNF) and the Exploratory Technologies Department at Pfizer, Inc. Justin received a B.A. in molecular, cellular, developmental biology from the University of California, Santa Cruz and an M.B.A. from the Rady School of Business at the University of California, San Diego. Outside of work, Justin is an avid sailor with dreams of spending more time on the high seas.
Steve Nurnberg leads product development at Nabsys. He is a 40-year veteran of life science instrumentation and consumables. Steve has an extensive track record of innovation and commercialization of products that have changed the way scientists and engineers solve problems, most recently using micro and nanofluidics He has held technical and senior management positions in startups to large public companies including Corning Medical, Waters, Millipore, PerSeptive Biosystems, Perkin Elmer, Applied Biosystems and IDEX Health & Science. He has a B.S. in Electrical Engineering from Cornell University.
Michael Kaiser joined Nabsys in 2012 and is responsible for leading the company’s software and informatics development efforts. He is a strong technical leader with a proven track record of developing and applying the technologies critical for creating break-through products. He has held technical and management positions in life science companies, for 30 years. His hardware and software IP are key components in novel instrumentation developed by Affymetrix and Covaris. Mike is especially proud of his participation in developing the Affymetrix GCS-3000 microarray scanner, which democratized microarray use and enabled vastly higher information content per array. The GCS-3000 sits on display today at the MIT Museum and the Broad Institute. Mike received his a B.S. in Electrical Engineering from the University of Rochester. When he’s not enmeshed in mathematical modeling and simulation, you can find Mike sailing in the waters of the northeast.
Jay Sage, PhD
Jay Sage joined Nabsys in October of 2014 bringing with him a diverse background in cell and molecular biology as well as protein and nucleic acid biochemistry. Dr. Sage has served as a core member of the R&D team at Nabsys, leveraging his experiences to drive sample preparation and technology development for electronic genome mapping. He received his B.S. in biochemistry and molecular biology from Michigan State University and his Ph.D. in biochemistry from the University of Massachusetts Medical School.
Jennifer Davis, PhD
Jennifer joined Nabsys in 2013 and has played a pivotal role in advancing the platform’s technology from its initial stages through product development and to commercialization. Over the past 10 years she has held various R&D roles at Nabsys and has been an effective cross-functional leader in the areas of assay development, detector development, and product development. Jennifer holds a Ph.D. in Molecular Pharmacology and Biotechnology from Brown University and a Bachelor’s Degree in Biochemistry and Molecular Biology from Clark University. While at Brown, she was a recipient of the NSF Graduate Research Fellowship and the Pharmacia Fellowship, which supported her research focused on the conversion of lignocellulose to high-value chemicals for bioenergy applications. Jennifer was attracted to Nabsys because of the technology’s potential to push the boundaries of genomics and impact the diagnosis of rare diseases. Beyond her professional pursuits, she enjoys spending time outdoors with her husband and two daughters.
John Thompson rejoined Nabsys in June 2023 as a principal applications scientist after having helped progress the technology while working there from 2011-2014 in a variety of R&D roles. In the intervening years, he developed a greater appreciation of the critical need for understanding structural variations while in senior research positions at other biotechs. He developed assays for diagnosing rare Mendelian diseases (Claritas), somatic variation in cancer (PGDx, now LabCorp) and AAV-based gene therapy for rare diseases (Homology Medicines). Prior to these positions, he led molecular biology and pharmacogenomic teams at Pfizer and developed novel applications for single-molecule sequencing at Helicos, including directly sequencing a 700,000-year-old DNA from what passed as horses at the time. That work was recounted in Nature and is one of his >100 peer-reviewed publications. Prior to joining industry, he was a Research Assistant Professor of Molecular Biology at Brown University, researching lambda site-specific DNA recombination. This work followed his PhD from the University of California, Berkeley and BS from Yale University, both in chemistry. When not characterizing genomes or training others how to do so, John can often be found playing tennis, traveling to the far corners of the earth, or babysitting grandchildren. He has pretty much given up on the Red Sox.
Tim joined Nabsys in 2015 bringing over 20 years of experience developing instrumentation for the life science industry. Tim is passionate about building successful engineering teams and developing direct reports and has deep experience in all phases of development, from feasibility to product launch. He is the named inventor on nine US patents and has successfully developed and launched multiple products at both Hologic (formerly Cytyc) and Applied Biosystems.
Ned joined Nabsys as Director of Product Management in March of 2023. Ned’s experience bringing innovative life science solutions to market spans a variety of OMICS and cell therapy related technologies with key areas of responsibility including strategic marketing, business planning, product development, commercialization, advanced technology collaborations, and product management. Prior to Nabsys, he worked at Agilent Technologies where he led a co-marketing arrangement with Biotek Instruments, eventually leading to their acquisition and also launched the Seahorse XF Pro analyzer, winner of the 2023 Select Science drug discovery product of the year. Earlier in his career, Ned launched a new Cell Analysis business division at Nikon Instruments capitalizing on his academic training in tissue and stem cell engineering at Harvard/MGH/Tissue Engineering, UCSD/Bioengineering, and Johns Hopkins/Cell Engineering. He lives outside of Boston, Massachusetts and is still active and involved with his alma mater, Johns Hopkins University, and the Boston affinity chapter of the Hopkins Biotech Network where he serves to mentor Hopkins students.
Elise joined the team in August 2023 and manages all corporate and product marketing responsibilities for Nabsys. Elise began her career in agency client management and has held several key marketing and product management roles at Illumina and Labcorp, including launching Illumina’s tier 1 products globally and managing a prenatal genetics portfolio for Labcorp Women’s Health and Genetics. She also helped helped scale a successful AI breast cancer detection start-up, CureMetrix, through the launch of cancerDx products. Elise is passionate about advancing precision medicine and making it widely accessible to all. Outside of her professional endeavors, she loves enjoying time outdoors with her family and friends. You can find her surfing, doing beachfront yoga and playing beach volleyball amongst other activities.
Sal joined Nabsys in October 2023 as the Director of North American Sales. He comes to Nabsys with over 12 years of high-performing industry experience in Territory and Strategic Account Management roles with leading companies in the genomics field including Beckman Coulter, Life Technologies, Thermo Fisher Scientific and PacBio. Prior to this, he worked for several years in the Respiratory Genetics division of the Channing Laboratory at Brigham and Women’s Hospital after earning a Bachelor of Science degree in Molecular Genetics from the University of Rochester. A native of Maine, currently living in Massachusetts, he enjoys numerous outdoor activities as well as coaching youth soccer.